Abstract
Since the discovery almost fifteen years ago that E2F transcription factors are key targets of the retinoblastoma protein (RB), studies of the E2F family have uncovered critical roles in the control of transcription, cell cycle and apoptosis. E2F proteins are encoded by at least eight genes, E2F1 through E2F8. While specific roles for individual E2Fs in mediating the effects of RB loss are emerging, it is also becoming clear that there are no simple divisions of labor among the E2F family. Instead, an individual E2F can function to activate or repress transcription, promote or impede cell cycle progression and enhance or inhibit cell death, dependent on the cellular context. While functional redundancy among E2Fs and the striking influences of cellular context on the effects of E2F loss or gain of function have prevented a simple delineation of unique functions within the E2F family, these complexities undoubtedly reflect the extensive regulation and importance of this transcription factor family.
Keywords: retinoblastoma protein, DNA damage, E2F deficient cells, transcription, hypophosphorylated RB
Current Molecular Medicine
Title: Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis
Volume: 6 Issue: 7
Author(s): James DeGregori and David G. Johnson
Affiliation:
Keywords: retinoblastoma protein, DNA damage, E2F deficient cells, transcription, hypophosphorylated RB
Abstract: Since the discovery almost fifteen years ago that E2F transcription factors are key targets of the retinoblastoma protein (RB), studies of the E2F family have uncovered critical roles in the control of transcription, cell cycle and apoptosis. E2F proteins are encoded by at least eight genes, E2F1 through E2F8. While specific roles for individual E2Fs in mediating the effects of RB loss are emerging, it is also becoming clear that there are no simple divisions of labor among the E2F family. Instead, an individual E2F can function to activate or repress transcription, promote or impede cell cycle progression and enhance or inhibit cell death, dependent on the cellular context. While functional redundancy among E2Fs and the striking influences of cellular context on the effects of E2F loss or gain of function have prevented a simple delineation of unique functions within the E2F family, these complexities undoubtedly reflect the extensive regulation and importance of this transcription factor family.
Export Options
About this article
Cite this article as:
DeGregori James and Johnson G. David, Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis, Current Molecular Medicine 2006; 6 (7) . https://dx.doi.org/10.2174/1566524010606070739
DOI https://dx.doi.org/10.2174/1566524010606070739 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Insertional Mutagenesis by Retroviral Vectors: Current Concepts and Methods of Analysis
Current Gene Therapy Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets Natural Products Targeting Cancer Stem Cells: A Revisit
Current Medicinal Chemistry NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science TGFß, a Potent Regulator of Tumor Microenvironment and Host Immune Response, Implication for Therapy
Current Molecular Medicine Measles Virus Induced Immunosuppression: Targets and Effector Mechanisms
Current Molecular Medicine Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
Current Pharmaceutical Design Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor
Current Drug Targets Whole Organism Based Techniques and Approaches in Early Stage Oncology Drug Discovery-Patents and Trends
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Medullary Thyroid Cancer: A Promising Model for Targeted Therapy
Current Molecular Medicine Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets The Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT) Family of Proteins: Transcriptional Modifiers with Multi-Functional Protein Interfaces
Current Molecular Medicine Elucidation of the Molecular Mechanisms of a Salicylhydrazide Class of Compounds by Proteomic Analysis
Current Cancer Drug Targets Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry A Review on Noscapine, and its Impact on Heme Metabolism
Current Drug Metabolism